<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04876677</url>
  </required_header>
  <id_info>
    <org_study_id>CLI-05993BA1-08</org_study_id>
    <nct_id>NCT04876677</nct_id>
  </id_info>
  <brief_title>Functional Respiratory Imaging Study</brief_title>
  <acronym>DARWiIN</acronym>
  <official_title>Open Label, Prospective Study to Evaluate the Effect of Step-up From Non-extra Fine Inhaled Corticosteroids/Long Acting Beta2 Agonist (ICS/LABA) Dry Powder Inhaler (DPI) to Extra Fine Triple Therapy With CHF5993 DPI on Airway Geometry and Lung Ventilation Using Functional Respiratory Imaging (FRI) in Subjects With Advanced Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the stepping-up effect from a double ICS/LABA DPI&#xD;
      therapy to a triple DPI therapy on airway geometry and lung ventilation&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>specific airway volume (siVaw) upon inspiration</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <description>CT-based airway volumes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>specific airway resistance (siRaw) upon inspiration</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <description>CT-based airway volumes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>siVaw upon expiration</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <description>calculated using Multidetector Computed Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>siRaw upon expiration</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <description>calculated using Multidetector Computed Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ventilation mapping</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <description>calculated using Multidetector Computed Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>perfusion mapping</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <description>calculated using Multidetector Computed Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>airway wall thickness upon inspiration</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <description>calculated using Multidetector Computed Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>imaged lobe and lung volumes at Total Lung Capacity (TLC) and Functional Residual Capacity (FRC)</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <description>calculated using Multidetector Computed Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>air trapping</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <description>calculated using Multidetector Computed Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>low attenuation score at TLC</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <description>calculated using Multidetector Computed Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentile 15th at TLC</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <description>calculated using Multidetector Computed Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>regional lung deposition</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <description>calculated using Multidetector Computed Tomography</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>CHF5993</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beclometasone Dipropionate (BDP) 100 μg/inhalation + Formoterol Fumarate (FF) 6 μg/inhalation + Glycopyrronium Bromide (GB) 12.5 µg/inhalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium</intervention_name>
    <description>Two inhalations bid: 4 inhalations; total daily dose of 400/24/50 μg BDP/FF/GB</description>
    <arm_group_label>CHF5993</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject's signed Informed Consent Form;&#xD;
&#xD;
          2. Male or female ≥ 40 years of age;&#xD;
&#xD;
          3. Current smokers or ex-smokers of at least 10 pack-years,&#xD;
&#xD;
          4. Established diagnosis of COPD&#xD;
&#xD;
          5. Post-BD Forced Expiratory Volume in one second/Forced Vital Capacity (FEV1/FVC) &lt; 0.7&#xD;
             and FEV1 ≤ 60% of predicted at V1&#xD;
&#xD;
          6. On a stable dose any non-extra fine ICS/LABA DPI twice daily regimen for at least 8&#xD;
             weeks before screening;&#xD;
&#xD;
          7. Presence of lung hyperinflation&#xD;
&#xD;
          8. Symptomatic subjects with COPD assessment test (CAT) score ≥ 10;&#xD;
&#xD;
          9. Documented history of ≥ 1 moderate or severe COPD exacerbation in the previous 12&#xD;
             months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating woman;&#xD;
&#xD;
          2. Exacerbations defined as a sustained and acute deterioration of subject's symptoms and&#xD;
             signs 30 days before screening;&#xD;
&#xD;
          3. A current asthma diagnosis;&#xD;
&#xD;
          4. Respiratory disorders other than COPD:&#xD;
&#xD;
          5. Cardiovascular diseases;&#xD;
&#xD;
          6. Evidence or history of other concurrent disease such as but not limited to&#xD;
             hyperthyroidism, diabetes mellitus or other endocrine disease;&#xD;
&#xD;
          7. Medical history or current diagnosis of narrow-angle glaucoma;&#xD;
&#xD;
          8. History of lung transplant or lung reduction surgery;&#xD;
&#xD;
          9. ECG criteria: any clinically significant abnormal 12-lead ECG that in the&#xD;
             investigator's opinion would affect efficacy or safety evaluation or place the&#xD;
             subjects at risk;&#xD;
&#xD;
         10. Laboratory abnormalities;&#xD;
&#xD;
         11. Alcohol/drug abuse;&#xD;
&#xD;
         12. Contra-indications to Investigational medical products (IMPs), based on investigator&#xD;
             judgement;&#xD;
&#xD;
         13. Documented Covid-19 diagnosis or its complications which have not resolved within 14&#xD;
             days prior to screening;&#xD;
&#xD;
        15. Positive molecular Covid-19 test within the last 72 hours before the remaining of&#xD;
        screening activities.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trial Info</last_name>
    <phone>0039 0521 2791</phone>
    <email>clinicaltrials_info@chiesi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>OLV Hospital Aalst</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Watripont</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre medical Erpent - Residence</name>
      <address>
        <city>Erpent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Benoit Martinot</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Zeno Knokke-Heist</name>
      <address>
        <city>Knokke</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wilfried De Backer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heilige Familie AZ</name>
      <address>
        <city>Reet</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ Delta</name>
      <address>
        <city>Roeselare</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ulrike Himpe</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Kenessey Albert Hospital</name>
      <address>
        <city>Balassagyarmat</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katalin Gömöri</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Koranyi Institute for TB and Pulmonology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katalin Udud</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CRU Hungary Ltd</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melinda Kovács Nagyné</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Hungary</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Beclomethasone</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

